import{_ as l,c as i,o as I,ag as g}from"./chunks/framework.Bw-5EFTY.js";const C="data:image/png;base64,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",Q="data:image/png;base64,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",B="data:image/png;base64,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",s="data:image/png;base64,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",J=JSON.parse('{"title":"水泡疾病","description":"","frontmatter":{"title":"水泡疾病","updated":"2025-03-30T14:46:09.000Z","created":"2025-02-09T15:25:00.000Z"},"headers":[],"relativePath":"other-specialties/皮膚科/水泡疾病.md","filePath":"other-specialties/皮膚科/水泡疾病.md"}'),e={name:"other-specialties/皮膚科/水泡疾病.md"};function E(a,A,u,t,r,k){return I(),i("div",null,A[0]||(A[0]=[g('<p>水泡疾病 2025年2月9日 下午 03:25</p><p><img src="'+C+'" alt="image1"></p><ul><li><p>編輯格式</p><ul><li>顏色註記方式 <ul><li>重要標題 : 母標題藍色(最暗)標記/子標題藍色(較暗,25%)標記</li><li>重要術式治療藥物 : <strong>綠色標記+粗體</strong></li><li>重要內文 : 紅色(標準色彩)/<strong>橘色+粗體(橘色那一欄第一個)</strong>(如果同色太醜就紅橘相間)</li><li>直接來複製顏色格式一定不會錯xd</li></ul></li></ul></li><li><p>名詞定義：</p><ul><li>天皰瘡(pemphigus)： <ul><li>一群皮膚、黏膜的自體免疫性水泡性疾病(autoimmune blistering disease)，有以下特徵： <ul><li>組織學特徵：因角質細胞(keratinocytes)間棘層鬆解(acantholysis)，形成表皮內水泡(intraepidermal blisters) <ul><li>棘層鬆解(acantholysis)：游離的表皮細胞形狀也從多角形變圓形(acantholytic cell)，使皮膚或黏膜發炎剝離產生水泡</li></ul></li><li>免疫學特徵：有針對角質細胞(keratinocytes)細胞表面的抗體</li></ul></li></ul></li><li>橋粒(Desmosomes)： <ul><li>主要功能是維持角質細胞間的連結</li><li>Desmoglein 1(Dsg1)：主要分佈於皮膚淺層、黏膜中含量低</li><li>Desmoglein 3(Dsg3)：主要分佈於皮膚基底層、口腔黏膜 <img src="'+Q+'" alt="image2"></li></ul></li></ul></li></ul><p>Dermatology 4th ed. p.584</p><ul><li>類天疱瘡抗原(Bullous pemphigoid antigen, BPAg)： <ul><li>位於連接基底層(stratum basale)和Basement membrane的半胞橋小體(hemidesmosome)上</li></ul></li><li>Nikolsky sign： <ul><li>在已有的水泡病灶邊緣輕微施壓，原本好的皮膚也會上下層分離，使得水泡病灶延伸擴大，代表細胞間的接合力很差</li></ul></li><li>Direct immunofluorescence(DIF)、Indirect immunofluorescence(IIF) <img src="'+B+'" alt="image3"></li><li>分類： <ul><li>尋常性天疱瘡(Pemphigus vulgaris, PV)</li><li>落葉型天疱瘡(Pemphigus foliaceus, PF) <ul><li>紅斑型天疱瘡(Pemphigus erythematosus, PE )=Senear-Usher syndrome</li></ul></li><li>類天疱瘡(Bullous pemphigoid, BP)</li><li>Dermatitis herpetiformis</li><li>IgA pemphigus=Linear IgA dermatosis</li><li>Paraneoplastic pemphigus</li><li>Drug-induced pemphigus <img src="'+s+'" alt="image4"></li></ul></li><li>病生理： <ul><li>免疫系統產生 IgG 自體抗體→攻擊皮膚、黏膜上皮細胞之間的細胞連結結構(橋粒，Desmosomes)→角質形成細胞(keratinocytes)間棘層鬆解(acantholysis)→形成水泡</li></ul></li><li>尋常性天疱瘡(Pemphigus vulgaris, PV)： <ul><li>流行病學： <ul><li>發病高峰：40-60歲</li></ul></li><li>病因： <ul><li>Type 2過敏反應</li><li>加劇因素：藥物(non-thiol drugs)、病毒、紫外線輻射、飲食(洋蔥、大蒜、韭菜…)</li><li>可被誘發</li></ul></li><li>臨床表現： <ul><li>好發部位： <ul><li>表皮：頭皮、臉部、軀幹、皮膚皺摺處(flexural area)</li><li>黏膜：口咽部最常見</li></ul></li><li>先從出現口腔黏膜潰瘍(&gt;50%)，數個月後皮膚才會開始出現病灶</li><li>皮膚病灶：卵圓形含清澈組織液，鬆且易破的水泡(flaccid vesicle/ bulla)， 破裂之後呈現表淺的糜爛(erosion)傷口，很痛，會輕微出血與結痂(crust)，來診病患多呈現身體大面積糜爛</li></ul></li><li>診斷： <ul><li>Anti-desmoglein IgG抗體：Dsg1 ± Dsg3</li><li>病理變化：表皮內的基底層(Stratum basale)與其上的表皮細胞分離，形成表皮層內裂縫(Intraepidermal cleft) ，裂縫中有許多游離的acantholytic cell，此種水泡稱為suprabasal blister</li><li>直接免疫螢光染色(Direct immunofluorescence, DIF )：IgG和C3沉積在細胞間隙(intercellular(IC) deposition)呈現網狀的IC pattern， 如右圖可見表皮層自基底層以上剝離，DIF呈網狀圖案</li><li>Nikolsky sign(+)</li></ul></li></ul></li><li>落葉型天疱瘡(Pemphigus foliaceus, PF)： <ul><li>簡介： <ul><li>抗體只攻擊Desmoglein 1(表皮)，故不會有口腔黏膜的病灶，且裂解位置更表淺，水泡通常不明顯易破而形成落屑或結痂的表面</li></ul></li><li>病因： <ul><li>Type 2過敏反應</li><li>加劇因素：藥物(Thiol drugs)</li></ul></li><li>臨床表現： <ul><li>分布位置：好發於背、前胸、臉、頭皮和腹部，通常不影響黏膜</li><li>紅斑基底、鱗屑/結痂性糜爛(scaly, crusted cutaneous erosions on an erythematous base)</li><li>發病初期通常僅見零散的結痂病灶，易被誤認為膿痂疹(impetigo)</li></ul></li><li>診斷： <ul><li>Anti-desmoglein IgG抗體：Dsg1</li><li>病理變化： <ul><li>表皮層分裂的位置在角質層下方(Stratum corneum=Subcorneal)，較PV的基底層上方(Suprabasal)更表淺，所以水泡更薄更容易破裂</li><li>也有acantholytic cell、IC pattern</li></ul></li><li>Nikolsky sign(+)</li></ul></li></ul></li><li>紅斑型天疱瘡(Pemphigus erythematosus, PE)： <ul><li>簡介： <ul><li>少見的亞型</li><li>只發生在臉上，分布位置和SLE的蝴蝶斑同</li><li>形成粗紅、有點脫屑的紅斑</li></ul></li></ul></li><li>流行性落葉型天疱瘡(Endemic pemphigus foliaceus )=叢林之火(Fogo Selvagem)： <ul><li>簡介： <ul><li>出現在南美洲亞馬遜河流域森林的一種流行性疾病，可影響同住家人同時罹患</li><li>症狀與落葉型天疱瘡(PF)完全相同</li></ul></li></ul></li><li>類天疱瘡(Bullous pemphigoid, BP)： <ul><li>流行病學： <ul><li>自體免疫水泡病中最常見的一種</li><li>發病高峰：60-80歲、腦中風及中樞神經病變者</li></ul></li><li>病因：Type 2過敏反應</li><li>病生理： <ul><li>自體抗體攻擊類天疱瘡抗原(Bullous pemphigoid antigen) BPAg1、BPAg2→活化補體及發炎反應→破壞基底層細胞與其下真皮層的聯結→表皮(epidermis)與真皮 (dermis)之間裂開</li></ul></li><li>臨床特徵： <ul><li>好發部位：腋下、腹股溝等皮膚皺摺處，約有10%病人會有口腔病灶</li><li>一開始皮膚呈現發紅的紅疹或類似尋麻疹的病灶，數月後才慢慢出現水泡</li><li>與PV相比，BP裂在較深層，故水泡看起來較大，厚而緊繃，較不容易破掉，為緊繃的大水泡(tense bullae)</li></ul></li><li>診斷： <ul><li>病理變化： <ul><li>基底層(Stratum basale )與其下的真皮層分離，形成表皮層下裂縫(Subepidermal cleft )，又稱 subepidermal blister</li><li>嗜中性球、嗜伊紅性細胞和淋巴球浸潤於真皮層上層</li><li>直接免疫螢光染色(Direct immunofluorescence, DIF)： IgG和 C3 沿著表皮與真皮之間的 Basement membrane zone(dermo-epidermal junction)沉積，呈線狀沉積(linear deposition)</li></ul></li><li>Nikolsky sign(-)</li></ul></li></ul></li><li>皰疹樣皮炎(Dermatitis herpetiformis) <ul><li>流行病學： <ul><li>發病高峰：15-40歲</li><li>♂ &gt; ♀</li><li>北歐人較常見</li></ul></li><li>病因： <ul><li>與麩質腸病變(gluten-sensitive enteropathy, GSE)、表皮IgA沉積相關 <ul><li>HLA-DQ2、HLA-DQ8</li><li>自體免疫抗體同時攻擊腸胃道及皮膚，免疫複合物(immunocomplex)沉積在皮膚內引發一連串發炎反應</li></ul></li></ul></li><li>臨床表現： <ul><li>慢性、反覆發作、很癢的水泡疾病</li><li>皮膚症狀： <ul><li>劇烈癢感的紅斑性蕁麻疹樣斑塊(erythematous urticarial plaques)和緊繃的小水泡(tense vesicles)，排列成皰疹狀(herpetiform arrangement)</li><li>抓破的小水泡結痂癒合後的膚色可能較淺或較深(Post-inflammatory hypo- or hyperpigmentation)</li><li>分布位置：對稱性分佈，好發於關節的伸側(extensor site)、背部、臀部，不會發生在口腔黏膜</li></ul></li><li>腸胃道症狀：長期腹瀉(乳糜瀉, celiac sprue)、營養不良</li></ul></li><li>診斷： <ul><li>病理變化： <ul><li>嗜酸性顆粒細胞性棘層水腫(eosinophilic spongiosis)與角質下膿皰(subcorneal pustules) <ul><li>無明顯棘層鬆解(minimal or no apparent acantholysis)</li></ul></li><li>直接免疫螢光染色(Direct immunofluorescence, DIF)：在真皮乳突處(dermal papillae)的頂端IgA顆粒狀沉積(granular deposition)</li></ul></li><li>Nikolsky sign(-)</li></ul></li></ul></li><li>Drug-induced pemphigus： <ul><li>病生理：藥物誘發產生針對Dsg 1、Dsg 3的抗體</li><li>病因：確切病理機制仍未完全釐清，但可能與多重因素相關 <ul><li>藥物(約佔已開發國家10%)：某些藥物的活性硫醇(sulfhydryl, -SH)基團可與橋粒小體抗原(desmosomal antigen complex)結合形成半抗原(hapten)→誘發針對橋粒小體的體液免疫反應→棘層鬆解(acantholysis)、表皮內水泡(intraepidermal blisters)的形成 <ul><li>Thiol drugs：penicillamine、ACEI(captopril、enalapril)：常引起pemphigus foliaceus</li><li>Non-thiol drugs：penicillin、cephalosporins、 vancomycin、高血壓藥物(Nifedipine、Propranolol)、piroxicam、Phenobarbital：常引起pemphigus vulgaris</li></ul></li></ul></li><li>臨床特徵： <ul><li>通常在用藥數週至數個月後發生</li></ul></li><li>診斷： <ul><li>病理變化： <ul><li>直接免疫螢光染色(Direct immunofluorescence, DIF)：約90%可在病灶周圍皮膚呈陽性表現</li><li>循環抗橋粒蛋白抗體(anti-desmoglein autoantibodies)：約70%可檢測到此抗體</li></ul></li></ul></li><li>治療： <ul><li>停藥：對於由含硫醇基(-SH)藥物誘發的天皰瘡，停藥後大多可自發緩解(spontaneous remission) <ul><li>非硫醇基(-SH)藥物引起者，停藥後不一定能夠自發緩解，可能仍需Corticosteroids或免疫抑制劑(如 Rituximab)治療</li></ul></li><li>支持性療法：類似於原發性天皰瘡，包括傷口護理、抗生素預防感染等</li></ul></li></ul></li><li>治療： <ul><li>治療目標：減少自體抗體的產生、控制疾病、減少併發症，並達到長期緩解</li><li>治療策略： <ul><li>主要依賴系統性皮質類固醇，並輔以免疫抑制劑以達到降低劑量、副作用最小化及早期病情控制</li><li>部分難治或抗藥病例，則可考慮加入高劑量IVIg、Rituximab及血漿交換等進階治療</li></ul></li><li>口服類固醇：治療首選，療效最快、最顯著的治療方式 <ul><li>劑量：初始劑量 1 mg/kg/day prednisolone</li><li>應每5~7天評估療效一次，以便調整劑量，若仍有新水泡繼續產生，則將藥量增加50-100%至無任何新水泡為止</li><li>2週內沒有產生任何新水泡，且80%水泡傷口都癒合了，就可以開始減藥</li></ul></li><li>IV類固醇：針對病情嚴重患者可直接用IV類固醇 <ul><li>脈衝式靜脈注射類固醇法(Pulse therapy)：每日IV 500mg methylprednisolone， 連續三日</li><li>可有效控制病情發展、可減少副作用</li></ul></li><li>免疫抑制劑：減少長期使用皮質類固醇的副作用 <ul><li>Azathioprine：作為類固醇的輔助治療 <ul><li>劑量：2–4 mg/kg/day</li><li>療效緩慢，可能要等2-3週</li><li>副作用：輕微，除了少數人出現噁心、嘔吐、肝功能異常、血球低下</li></ul></li><li>Methotrexate (MTX)： <ul><li>療效快速，服用劑量低，適合無法吞太多藥物的老人家</li><li>肝毒性，故無法長期服用，有些人會有嚴重的噁心嘔吐，故腎功能不好者需小心使用</li></ul></li><li>Cyclophosphamide：做為自體免疫疾病的輔助治療或脈衝治療</li><li>Mycophenolate mofetil(CellCept)：近幾年來較受矚目的藥物之一 <ul><li>劑量：一般2-3 g/day</li><li>在美國有些專治免疫水泡疾病的醫學中心，已把此藥設定在類固醇之後的首選第二線治療藥物</li><li>副作用：骨髓抑制較少，但腸胃毒性較顯著</li></ul></li><li>Rituximab： <ul><li>也可以有效去除製造自體抗體的免疫細胞，可有效治療難治天疱瘡</li><li>因為B淋巴球在治療後大量減少， 必須密切注意感染的副作用</li></ul></li></ul></li><li></li></ul></li></ul>',5)]))}const o=l(e,[["render",E]]);export{J as __pageData,o as default};
